Year All2024202320222021 KemPharm Announces Promotion of Sven Guenther, Ph.D., to Chief Scientific Officer and Christal Mickle, M.A., to Chief Product Development Officer 01-11-2023 KemPharm Announces Board and Leadership Changes to Support its Transformation into a Leading Rare Disease Company 01-09-2023 KemPharm Announces Initiation of Phase 2 Clinical Trial Investigating KP1077 for the Treatment of Idiopathic Hypersomnia (IH) 12-21-2022 KemPharm Announces Appointment of Christopher Posner as New Independent Director 11-29-2022 KemPharm Receives FDA Orphan Drug Designation for Serdexmethylphenidate (SDX) for the Treatment of Idiopathic Hypersomnia (IH) 11-18-2022 KemPharm Reports Third Quarter 2022 Results 11-09-2022 KemPharm to Report Third Quarter 2022 Financial Results 11-01-2022 KemPharm Supports Niemann-Pick Awareness Month During October and Global Niemann-Pick Awareness Day on October 19th 10-04-2022 KemPharm Announces Positive Topline Data from Phase 1 Clinical Trial Evaluating Cardiovascular Safety of Serdexmethylphenidate (SDX) 09-28-2022 KemPharm to Present at the H.C. Wainwright 24th Annual Global Investment Conference 09-01-2022
KemPharm Announces Promotion of Sven Guenther, Ph.D., to Chief Scientific Officer and Christal Mickle, M.A., to Chief Product Development Officer 01-11-2023
KemPharm Announces Board and Leadership Changes to Support its Transformation into a Leading Rare Disease Company 01-09-2023
KemPharm Announces Initiation of Phase 2 Clinical Trial Investigating KP1077 for the Treatment of Idiopathic Hypersomnia (IH) 12-21-2022
KemPharm Receives FDA Orphan Drug Designation for Serdexmethylphenidate (SDX) for the Treatment of Idiopathic Hypersomnia (IH) 11-18-2022
KemPharm Supports Niemann-Pick Awareness Month During October and Global Niemann-Pick Awareness Day on October 19th 10-04-2022
KemPharm Announces Positive Topline Data from Phase 1 Clinical Trial Evaluating Cardiovascular Safety of Serdexmethylphenidate (SDX) 09-28-2022
